Result of AGM
RNS & Investor News
OptiBiotix showcases weight management product at Health Ingredients Europe
25 November 2014
OptiBiotix Health Plc(AIM: OPTI), the Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that its weight management yoghurt will be showcased at the Health Ingredients Europe conference in Amsterdam from December 2nd - 4th 2014. The product will be available on the Nizo Food Research stand and will be supported by product samples. The stand number is J2.
Health Ingredients Europe (HiE) is the largest European exhibition for health ingredients, with more than 500 global suppliers registered to attend. HiE promotes itself as the leading European venue to engage with business partners and solution providers in the $1 trillion health, natural and nutritional food and beverage industry.
The weight management yoghurt brings together the joint expertise of OptiBiotix Health and Nizo Food Research. OptiBiotix is responsible for the weight management formulation, created by world experts in satiation (the feeling of fullness), metabolism and how microbes harvest energy in the gut whilst Nizo's specialist expertise lies in the manufacture of dairy products and using taste and texture to improve satiation.
Stephen O'Hara, CEO of OptioBiotix Health plc commented: "We are delighted to be presenting our unique weight management product at this year's HiE exhibition and exploring partnership opportunities with the many global suppliers attending this exhibition."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
|Tel: 020 7469 0936|
|Walbrook PR Ltd||Tel: 020 7933 8780 or [email protected]|
|Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
About NIZO - www.nizo.com
NIZO is one of the most advanced, independent contract research companies in the world and works with both small and multinational food and ingredient companies to develop and produce innovative products for the food and drink industry. NIZO has one of the largest food-grade pilot plants in Europe, and more than 65 years' experience and expertise in product manufacture
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020